4.8.2Segment

Cardiovascular Devices

Device manufacturers producing pacemakers, stents, electrophysiology catheters, and structural heart repair products.

5
Verticals

Overview

Cardiovascular Devices covers manufacturers of pacemakers, defibrillators, stents, electrophysiology catheters, and structural-heart products. Structural heart — transcatheter aortic valve replacement (TAVR, led by Edwards) and mitral/tricuspid repair — and electrophysiology (including pulsed-field ablation) are the high-growth frontiers.

It is a large, innovation-intensive category dominated by Medtronic, Abbott, Boston Scientific, and Edwards, with aging demographics and minimally invasive procedure shifts driving demand. The federal code (electromedical apparatus) is broad, also spanning neuromodulation and other electromedical devices.

Market snapshot

Market size
~$40B
Growth
~3.7%CAGR (2017–22, nominal)
Companies
~780 firms
Firms by employee count

59.9% of firms have fewer than 20 employees: 467 micro-businesses, below most mandates.

The investable universe313 firms with 20+ employees
20–99
14847%
100–499
7223%
500+
9330%

~780 U.S. makers of pacemakers, defibrillators, stents, and structural-heart products, dominated by Medtronic, Abbott, Boston Scientific, and Edwards. Structural heart (TAVR) and electrophysiology are the growth frontiers; ~3.7%/yr overall. The federal code (electromedical apparatus) is broad, also spanning neuromodulation, so it captures more than cardiovascular alone.

NAICS 334510. U.S. Census Bureau — 2022 Statistics of U.S. Businesses; U.S. Census Bureau — 2022 Economic Census.

Business model & economics

Revenue model

Implant and device sales plus procedure-driven consumables

Key economics

Revenue per firm
$50,724,053
Revenue per employee
$416,677
Employees per firm
118.3
Recurring revenue
Moderate–High

procedure and replacement-driven

EBITDA margin
20–30%
Capex intensity
High

Characteristics

  • Balanced cost base — payroll is 26% of revenue, leaving room to scale margin without cutting staff
  • Moderate strategic-buyer pool — 93 firms exceed 500 employees; a scaled asset has buyers, but not many
  • Structural heart (TAVR) and EP are the growth frontiers.
  • Aging demographics and minimally invasive shifts drive demand.
  • Dominated by Medtronic, Abbott, Boston Scientific, Edwards.

NAICS 334510. U.S. Census Bureau — 2022 Statistics of U.S. Businesses; U.S. Census Bureau — 2022 Economic Census.

M&A deal context

Deal activityHigh

Who’s acquiring

  • Cardiovascular-device strategics
  • Diversified medtech platforms
  • VC-backed innovators

What’s driving deals

  • Acquisition of structural-heart and EP innovation.
  • Aging-demographic and procedure-shift demand.
  • Pulsed-field ablation and next-gen EP competition.

Verticals in this segment

Find Cardiovascular Devices acquisition targets

Search Acquisera’s index for companies classified under Cardiovascular Devices (4.8.2) and build a targeted deal pipeline.

Search companies